Cargando…
Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates
At the end of 2019, the new coronavirus caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly raged, bringing a severe public health crisis to the world. It is urgent to discover suitable drugs and treatment regimens against this coronavirus disease 2019 (COVID-19) and rela...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237387/ https://www.ncbi.nlm.nih.gov/pubmed/36304139 http://dx.doi.org/10.1016/j.ejmcr.2021.100003 |
_version_ | 1783714717206839296 |
---|---|
author | Wang, Qian Liu, Zhenming |
author_facet | Wang, Qian Liu, Zhenming |
author_sort | Wang, Qian |
collection | PubMed |
description | At the end of 2019, the new coronavirus caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly raged, bringing a severe public health crisis to the world. It is urgent to discover suitable drugs and treatment regimens against this coronavirus disease 2019 (COVID-19) and related diseases. Based on the previous knowledge and experience in treating similar diseases, researchers have come up with hundreds of possible drug candidates in the shortest possible time. Based on surface plasmon resonance (SPR) technology, this review summarized the application of SPR technology in COVID-19 research from four aspects: the invasion mode of SARS-CoV-2 into host cells, antibody drug candidates for the treatment of COVID-19, small molecule drug repurposing and vaccines for COVID-19. SPR technology has gradually become a powerful tool to study the interaction between drugs and targets due to its high efficiency, automation, labeling-free and high data resolution. The use of SPR technology can not only obtain the affinity data between drugs and targets, but also clarify the binding sites and mechanisms of drugs. We hope that this review can provide a reference for the subsequent application of SPR technology in antiviral drug development. |
format | Online Article Text |
id | pubmed-8237387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82373872021-06-28 Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates Wang, Qian Liu, Zhenming Eur J Med Chem Rep Article At the end of 2019, the new coronavirus caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly raged, bringing a severe public health crisis to the world. It is urgent to discover suitable drugs and treatment regimens against this coronavirus disease 2019 (COVID-19) and related diseases. Based on the previous knowledge and experience in treating similar diseases, researchers have come up with hundreds of possible drug candidates in the shortest possible time. Based on surface plasmon resonance (SPR) technology, this review summarized the application of SPR technology in COVID-19 research from four aspects: the invasion mode of SARS-CoV-2 into host cells, antibody drug candidates for the treatment of COVID-19, small molecule drug repurposing and vaccines for COVID-19. SPR technology has gradually become a powerful tool to study the interaction between drugs and targets due to its high efficiency, automation, labeling-free and high data resolution. The use of SPR technology can not only obtain the affinity data between drugs and targets, but also clarify the binding sites and mechanisms of drugs. We hope that this review can provide a reference for the subsequent application of SPR technology in antiviral drug development. The Authors. Published by Elsevier Masson SAS. 2021-07 2021-06-28 /pmc/articles/PMC8237387/ /pubmed/36304139 http://dx.doi.org/10.1016/j.ejmcr.2021.100003 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Wang, Qian Liu, Zhenming Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates |
title | Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates |
title_full | Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates |
title_fullStr | Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates |
title_full_unstemmed | Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates |
title_short | Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates |
title_sort | recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237387/ https://www.ncbi.nlm.nih.gov/pubmed/36304139 http://dx.doi.org/10.1016/j.ejmcr.2021.100003 |
work_keys_str_mv | AT wangqian recentprogressofsurfaceplasmonresonanceinthedevelopmentofcoronavirusdisease2019drugcandidates AT liuzhenming recentprogressofsurfaceplasmonresonanceinthedevelopmentofcoronavirusdisease2019drugcandidates |